COVID antibody drug for kids study ends early after just 2 patients
NCT ID NCT05092581
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 28 times
Summary
This study tested a single dose of two monoclonal antibodies (casirivimab+imdevimab) given intravenously to children hospitalized with COVID-19. The goal was to measure how the drug behaves in the body and check for side effects. Only 2 children were enrolled before the study was terminated early, so results are very limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID - 19 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Le Bonheur Children's Hospital
Memphis, Tennessee, 38103, United States
-
State University of New York at Stony Brook
Stony Brook, New York, 11794, United States
Conditions
Explore the condition pages connected to this study.